The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease
Open accessAbstract
BACKGROUND: Several steatosis biomarkers are available with limited independent validation. AIM: To determine diagnostic value and limitations of several steatosis biomarkers using liver biopsy as reference standard in a large cohort of patients with suspected NAFLD. METHODS: Three hundred and twenty-four consecutive liver biopsies were included. Histological steatosis was categorised as none (<5%), mild (5-33%), moderate (33-66%) and severe (>66%). Five steatosis biomarkers were measured: fatty liver index (FLI), NAFLD liver fat score (NAFLD-LFS), hepatic steatosis index (HSI), visceral adiposity index (VAI) and triglyceride × glucose (TyG) index. RESULTS: Steatosis grades prevalence was: none 5%, mild 39%, moderate 30% and severe 27%. Except for VAI, the steatosis biomarkers showed a linear trend across the steatosis grades. However, their correlation with the histological amount of steatosis was only weak-moderate. All steatosis biomarkers had an adequate diagnostic accuracy for the presence of steatosis: AUROCs for FLI, LFS, HSI, VAI and TyG were 0.83, 0.80, 0.81, 0.92 and 0.90. However, their ability to quantify steatosis was poor: none of them distinguished between moderate and severe steatosis and the AUROCs for predicting steatosis >33% were 0.65, 0.72, 0.65, 0.59 and 0.59 for FLI, LFS, HSI, VAI and TyG. Both fibrosis and inflammation significantly confounded the association between steatosis biomarkers and steatosis. The steatosis biomarkers were all correlated with HOMA-IR, independent from histological steatosis. CONCLUSIONS: All five steatosis biomarkers can diagnose steatosis and are correlated with insulin resistance. They are confounded by fibrosis and inflammation, and do not accurately quantify steatosis; this may limit their clinical utility. More research is needed to identify truly independent and quantitative markers of steatosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Petersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Ryysy, L., Häkkinen, A. M., Goto, T., Vehkavaara, S., Westerbacka, J., Halavaara, J., & Yki-Järvinen, H. (2000) · Diabetes · doi:10.2337/diabetes.49.5.749 · Cited by 431
Nascimbeni, F., Lebray, P., Fedchuk, L., Oliveira, C. P., Alvares-da-Silva, M. R., Varault, A., Ingiliz, P., Ngo, Y., de Torres, M., Munteanu, M., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.037 · Cited by 82
Self-citation
Cited by
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494
Quek, J., Chan, K. E., Wong, Z. Y., Tan, C., Tan, B., Lim, W. H., Tan, D. J. H., Tang, A. S. P., Tay, P., Xiao, J., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00317-x · Cited by 749
Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.173 · Cited by 397
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Kim, D., Vazquez‐Montesino, L. M., Li, A. A., Cholankeril, G., & Ahmed, A. (2020) · Hepatology · doi:10.1002/hep.31158 · Cited by 177
Breakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Self-citationKawaguchi, T., Charlton, M., Kawaguchi, A., Yamamura, S., Nakano, D., Tsutsumi, T., Zafer, M., & Torimura, T. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1723751 · Cited by 122
Atabaki-Pasdar, N., Ohlsson, M., Viñuela, A., Frau, F., Pomares-Millan, H., Haid, M., Jones, A. G., Thomas, E. L., Koivula, R. W., Kurbasic, A., et al. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003149 · Cited by 97
Vilar-Gomez, E., Vuppalanchi, R., Gawrieh, S., Pike, F., Samala, N., & Chalasani, N. (2023) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002222 · Cited by 39
Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
Kechagias, S., Ekstedt, M., Simonsson, C., & Nasr, P. (2022) · Hormones · doi:10.1007/s42000-022-00377-8 · Cited by 39
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Cho, E. J., Chung, G. E., Yoo, J.-J., Cho, Y., Lee, K. N., Shin, D. W., Kim, Y. J., Yoon, J.-H., Han, K., & Yu, S. J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02408-7 · Cited by 17
Metadata
- Authors
- Fedchuk, L., Nascimbeni, F., Pais, R., Charlotte, F., Housset, C., Ratziu, V., & the LIDO Study Group
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2014-09-29
- Volume
- 40
- Issue
- 10
- Pages
- 1209-1222
- ISSN
- 0269-2813 (ISSN-L)
- OpenAlex
- W2062686278
- Cited by
- 500
- References
- 7
- FWCI
- 14.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
